for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Daewoong Pharmaceutical Co., Ltd.

069620.KS

Latest Trade

105,000.00KRW

Change

2,500.00(+2.44%)

Volume

221,799

Today's Range

103,000.00

 - 

111,000.00

52 Week Range

63,200.00

 - 

163,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Daewoong Pharmaceutical Unveils Phase 3 Clinical Data Of Fexuprazan, A Novel Potassium-Competitive Acid Blocker

May 8 (Reuters) - Daewoong Pharma <069620.KS>::DAEWOONG PHARMACEUTICAL UNVEILS PHASE 3 CLINICAL DATA OF FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER.DAEWOONG PHARMA - FEXUPRAZAN SHOWED 99% OF MUCOSAL HEALING RATE AT WEEK 8 AND WAS WELL TOLERATED IN PATIENTS.DAEWOONG PHARMA - FEXUPRAZAN ALSO SHOWED IMPROVED SYMPTOM RELIEF.DAEWOONG PHARMA - ATYPICAL SYMPTOM SUCH AS COUGH WAS ALSO IMPROVED WITH TREATMENT OF FEXUPRAZAN.DAEWOONG PHARMA - IN PATIENTS WITH MODERATE TO SEVERE SYMPTOMS, FEXUPRAZAN EXHIBITED SIGNIFICANTLY FASTER, BETTER HEARTBURN RELIEF VERSUS ESOMEPRAZOLE.

Avacta And Daewoong Establish Joint Venture

Jan 8 (Reuters) - Avacta Group PLC <AVTG.L>::AVACTA AND DAEWOONG ESTABLISH JOINT VENTURE.COLLABORATION TO DEVELOP NEXT GENERATION CELL AND GENE THERAPIES INCORPORATING AFFIMER PROTEINS.TO ESTABLISH JV IN SOUTH KOREA WITH DAEWOONG PHARMACEUTICAL FOR COLLABORATION, LICENSE AGREEMENT.AVACTA'S SHAREHOLDING IN JOINT VENTURE IS 45%.JV TO BE OPERATIONALLY MANAGED BY SENG-HO JEON, CEO OF DAEWOONG, WITH A BOARD COMPOSED OF REPRESENTATIVES OF BOTH AVACTA AND DAEWOONG.

Daewoong Acquires Shares Worth 5 Billion Won In Daewoong Pharma

May 13 (Reuters) - Daewoong Co Ltd <003090.KS>::SAYS ACQUIRES SHARES WORTH 5 BILLION WON ($4.22 million) IN DAEWOONG PHARMA <<<069620.KS>>>.

Daewoong Pharma Says Signs $12 Mln Worth Deals In New Zealand, Israel, Ukraine

Dec 20 (Reuters) - Daewoong Pharma <069620.KS>::SAYS SIGNS DEAL WORTH $12 MILLION TO EXPORT ITS BOTOX PRODUCT IN NEW ZEALAND, ISRAEL, UKRAINE.AIMS TO RELEASE IN 2020.

Daewoong Pharma to pay annual cash dividend as 600 won/share

March 1 (Reuters) - Daewoong Pharma <069620.KS> ::Says it plans to pay annual cash dividend as 600 won/share to shareholders of record on Dec. 31, 2017.

Daewoong Pharma to pay annual dividend as 600 won/share for FY 2016

Daewoong Pharma <069620.KS> : Says it will pay annual cash dividend as 600 won/share for FY 2016, to shareholders of record on Dec. 31, 2016 .Total dividend amount is 6.19 billion won.

Daewoong Pharma signs contract worth 72.8 bln won

Daewoong Pharma <069620.KS> : Says it signs contract with Abbott Products Operations Ag (Switzerland) to export pitavastatin calcium to Thailand and other three countries in South-East Asia, on Nov. 2 .Contract amount is 72.80 billion won.

Daewoong Pharma declares annual cash dividend for 2015

Daewoong Pharma:To pay annual cash dividend of 700 won per share for 2015.Dividend payment to shareholders of record on Dec. 31, 2015.Total dividend amount 7,224,609,000 won.

Daewoong Pharma announces patent granted

Daewoong Pharma:Receives a patent on Jan. 4, for a pharmaceutical composition for treating gastrointestinal disorders.Patent number of 10-2015-0147513.

Daewoong Pharma to invest in Hanall Biopharma

Daewoong Pharma:To invest 104,620,000,000 won to get 15,500,000 shares of Hanall Biopharma.To hold 30.2 pct stake in Hanall Biopharma.Expected settlement date July 30.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up